xeruborbactam isoboxil   Click here for help

GtoPdb Ligand ID: 13241

Synonyms: QPX-7831 | QPX7831
Compound class: Synthetic organic
Comment: QPX7831 is an orally bioavailable prodrug of xeruborbactam [1].
The chemical structure of QPX7831 is identical to that for the INN xeruborbactam isoboxil (proposed list 132, Feb. 2025).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 82.06
Molecular weight 322.09
XLogP 1.46
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C(=O)OCOC(=O)C1=C2C(=CC=C1F)[C@@]3([H])C[C@@]3([H])B(O)O2
Isomeric SMILES [H][C@]12C[C@@]1([H])B(O)OC3=C2C=CC(=C3C(=O)OCOC(C(C)C)=O)F
InChI InChI=1S/C15H16BFO6/c1-7(2)14(18)21-6-22-15(19)12-11(17)4-3-8-9-5-10(9)16(20)23-13(8)12/h3-4,7,9-10,20H,5-6H2,1-2H3/t9-,10-/m1/s1
InChI Key FCXHIXHOQJYLTG-NXEZZACHSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Qpex Biopharma are developing an orally administered combination of QPX7831 + β-lactam antibacterial (proposed trademark ORAvance™) as a treatment for infections caused by carbapenem-resistant and Extended Spectrum Beta-Lactamase (ESBL)-producing Enterobacterales.
QPX7831 has completed a Phase 1 trial (NCT04578873) to assess safety, tolerability, and pharmacokinetics in healthy participants. Further Phase 1 studies (not yet recruiting, March 2024) will evaluate a combination of QPX7831 and ceftibuten in healthy participants and those with renal impairment (NCT06079775 and NCT06157242).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06079775 P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants Phase 1 Interventional Qpex Biopharma, Inc.
NCT06157242 PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment Phase 1 Interventional Qpex Biopharma, Inc.
NCT04578873 Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults Phase 1 Interventional Qpex Biopharma, Inc.